Mathieu U.
- Country
- France
- Department
- Gastroenterology
Research Overview
- Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Duvakitug for Induction Therapy in Moderately to Severely Active Crohn's Disease
- Efficacy and Safety of Duvakitug for Maintenance Therapy in Participants with Moderately to Severely Active Crohn’s Disease: A Phase 3, Randomized, Placebo-Controlled Study
- Comparison of Vedolizumab, Filgotinib, Ustekinumab, and Infliximab as First-Line Advanced Therapy to Maintain Remission in Patients with Ulcerative Colitis
Data & Insights
Has run more than one trial at 427 of 624 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating inflammatory bowel conditions, with particular emphasis on Crohn's disease and ulcerative colitis. Their research encompasses both conventional and innovative therapeutic approaches.
- Moderately to severely active Crohn's disease treatment
- Ulcerative colitis therapy optimization
- Post-operative Crohn's disease management
Novel Therapeutic Approaches
The investigator explores advanced biological therapies and combination treatments for inflammatory bowel conditions, including novel agents like RO7790121, obefazimod, and guselkumab.
- Biological therapy evaluation
- Combination therapy assessment
- Treatment response monitoring
Microbiota-Based Interventions
A significant focus is placed on fecal microbiota transplantation research for various gastrointestinal conditions, including pouchitis and inflammatory bowel disease management.
- Fecal microbiota transplantation protocols
- Recurrent pouchitis treatment
- Microbiome modulation strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.